fluorodeoxyglucose f18 has been researched along with Neuroendocrine Tumors in 193 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.55) | 18.2507 |
| 2000's | 27 (13.99) | 29.6817 |
| 2010's | 112 (58.03) | 24.3611 |
| 2020's | 51 (26.42) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G; Wang, Z; Wu, Y; Zhang, B; Zhou, Z | 1 |
| Caplin, ME; Furtado O'Mahony, L; Gnanasegaran, G; Hayes, AR; Navalkissoor, S; Quigley, AM; Toumpanakis, C | 1 |
| Bailey, DL; Chan, DL; Roach, PJ | 1 |
| Aparici, CM; Eads, JR; Lee, H; Moore, SE; Nakamoto, R; Pantel, AR; Pryma, DA | 1 |
| Baykal Koca, S; Çermik, TF; Ergül, N; Şahin, R; Yücetaş, U | 1 |
| Hod, N; Lantsberg, S; Levin, D | 1 |
| Binkovitz, L; Bois, MC; Layman, AJ; Nguyen, B; Shah, A | 1 |
| Ikeda, H; Kanamori, T; Kometani, M; Nakano, Y; Nomura, C; Shima, KR; Takamura, T; Takeshita, Y; Tanaka, T; Yoneda, T | 1 |
| Akhurst, T; Hicks, RJ; Iravani, A; Parihar, AS | 1 |
| Berti, S; El Khouzai, B; Gregianin, M; Guglielmo, P; Muccioli, S; Pesella, F; Sartorello, A | 1 |
| Grineva, E; Mitrofanova, L; Ryzhkova, D; Schlyakhto, E; Tsoy, U | 1 |
| Barrs, C; Bhosale, P; Francis, IR; Iravani, A; Itani, M; Mhlanga, J; Morani, A; Yano, M; Zulfiqar, M | 1 |
| Brixi, H; Cadiot, G; Deguelte, S; Lelièvre, M; Morland, D; Perrier, M; Triumbari, EKA | 1 |
| Agrawal, A; Bal, M; Bhandare, M; Chaudhari, V; Choudhury, S; Ostwal, V; Purandare, N; Puranik, A; Ramaswamy, A; Rangarajan, V; Shah, S; Shrikhande, SV | 1 |
| Abenavoli, EM; Antonuzzo, L; Berti, V; Briganti, V; Danti, G; Grosso, AM; Lavacchi, D; Linguanti, F; Matteini, M; Miele, V; Mini, E; Mungai, F; Novelli, L; Sciagrà, R; Vaggelli, L | 1 |
| Baron-Hay, S; Batty, K; Bernard, EJ; Boyle, F; Chan, DL; Clarke, SJ; Diakos, CI; Guminski, A; Pavlakis, N; Taylor, AM | 1 |
| Buck, AK; Hartrampf, PE; Higuchi, T; Kosmala, A; Lindner, T; Michalski, K; Schirbel, A; Schlötelburg, W; Serfling, SE; Weich, A; Werner, RA | 1 |
| Bailey, DL; Bernard, E; Caplin, ME; Chan, DL; Conner, A; Flamen, P; Furtado O'Mahony, L; Gnanasegaran, G; Hayes, AR; Karfis, I; Marin, C; Marin, G; Mileva, M; Navalkissoor, S; Pavlakis, N; Roach, P; Schembri, G; Toumpanakis, C; Vanderlinden, B | 1 |
| Du, C; Shao, G; Tian, R; Wang, F; Xie, Q; Yang, Z; Yao, X; Yu, F; Yu, J; Zang, S; Zhang, C; Zhang, P | 1 |
| Afchain, P; Baudin, É; Delabie, P; Hentic, O; Montravers, F; Rusu, T | 1 |
| Hayashi, S; Izu, A; Kawachi, R; Masuda, S; Sakakibara, M; Sakurai, H; Sato, D; Shimamura, M | 1 |
| Henderson, A; Khatri, W; Rowe, SP; Solnes, LB; Spiro, E | 1 |
| Fujii, H; Fujiwara, Y; Ishido, N; Kadowaki, Y; Komoto, S; Kubota, T; Matano, T; Okino, T; Okubo, Y; Shirasaka, D; Watanabe, A | 1 |
| Al Darazi, M; Al Mahmasani, L; Charafeddine, M; Chehade, L; El Jebai, M; Elias, C; Haidar, M; Shamseddine, A; Temraz, S | 1 |
| Bagnacci, G; Bellan, C; Bertelli, P; Di Martino, V; Di Meglio, N; Luzzi, L; Mazzei, MA; Perrella, A; Volterrani, L | 1 |
| Cai, J; Hu, X; Li, D; Wang, P; Wang, R | 1 |
| Auernhammer, CJ; Bartenstein, P; Cyran, CC; Ebner, R; Fabritius, MP; Grawe, F; Hinterberger, A; Ingenerf, M; Knösel, T; Kunz, WG; Lohse, A; Mansournia, S; Ricke, J; Rübenthaler, J; Schmid-Tannwald, C; Schnitzer, ML; Sheikh, GT; Soltani, V; Spitzweg, C; Winkelmann, M | 1 |
| Chen, S; Lin, Z; Miao, W; Wang, C | 1 |
| Wan, DQ | 1 |
| Auernhammer, CJ; Cyran, C; Ricke, J; Todica, A; Winter, KS | 1 |
| Bailey, DL; Bernard, EJ; Chan, DL; Clarke, S; Johnson, M; Pavlakis, N; Roach, PJ; Schembri, G | 1 |
| Baum, RP; Kulkarni, HR; Zhang, J | 1 |
| Baratto, L; Duan, H; Iagaru, A | 1 |
| Calderoni, L; Castellucci, P; Fanti, S; Telo, S; Vichi, S; Zagni, F | 1 |
| Akhurst, T; Hicks, RJ; Jefford, M; Kuru, N; Liauw, W; Link, E; Lung, MS; Michael, M; Pavlakis, N; Thomson, B; Wyld, DK | 1 |
| Dong, A; Dong, H; He, Q; Ji, X; Zuo, C | 1 |
| Angamuthu, M; Das, CJ; Kumar, R; Subudhi, TK; Yadav, D | 1 |
| Gaujoux, S; Libé, R; Meyer, C; Paepegaey, AC; Rouquette, A | 1 |
| Bagni, O; Cianni, R; Filippi, L; Schillaci, O | 1 |
| Bignotto, A; Cecchin, D; Evangelista, L; Ravelli, I; Zucchetta, P | 1 |
| Beg, M; De Blanche, L; Kandathil, A; Kazmi, S; Subramaniam, RM; You, H | 1 |
| Andreasi, V; Bettinardi, V; Doraku, J; Falconi, M; Gianolli, L; Mapelli, P; Muffatti, F; Partelli, S; Pasetto, S; Picchio, M; Presotto, L; Rancoita, PMV; Salgarello, M | 1 |
| Basu, S; Bhandare, M; Chaudhari, V; Ostwal, V; Parghane, RV; Ramaswamy, A; Shrikhande, SV; Talole, S | 1 |
| Cadiot, G; de Mestier, L; Do Cao, C; Hentic, O; Perrier, M; Walter, T | 1 |
| Basu, S; Bhandare, MS; Bhargava, P; Chaudhari, V; Ostwal, V; Parghane, RV; Ramaswamy, A; Shah, M; Shrikhande, SV; Srinivas, S | 1 |
| Berthelsen, AK; Binderup, T; Federspiel, B; Johnbeck, CB; Kjaer, A; Knigge, U; Langer, SW; Loft, A; Mortensen, J; Oturai, P | 1 |
| Chen, L; Lv, J; Shi, H; Xiu, Y; Yin, H | 1 |
| Bodei, L; Bongiovanni, A; Caroli, P; Cittanti, C; Di Iorio, V; Diano, D; Grana, CM; Grassi, I; Ibrahim, T; Monti, M; Nicolini, S; Paganelli, G; Pieri, F; Sansovini, M; Sarnelli, A; Severi, S | 1 |
| Du, Z; Guan, Y; Huang, Q; Lu, L; Ren, S; Wang, H; Xie, F; Zhu, W | 1 |
| Arslan, E; Beyhan, E; Çermik, TF; Erol, Ö; Şahin, R | 1 |
| Imperiale, A; Meuter, L; Pacak, K; Taïeb, D | 1 |
| Han, S; Kim, TH; Lee, HS; Ryoo, BY; Ryu, JS; Woo, S; Yoo, C | 1 |
| Assi, HA; Hornbacker, K; Kunz, PL; Shaheen, S; Silberman, R; Wittenberg, T | 1 |
| Chen, Y; Liu, H; Zhang, W; Zhang, Y | 1 |
| Bohmer, R; Burgess, JR; Kornaczewski Jackson, ER; Pointon, OP | 1 |
| Cuccurullo, V; Di Stasio, GD; Mansi, L; Prisco, MR | 1 |
| Hindié, E | 1 |
| Bailey, DL; Barnes, T; Bernard, EJ; Chan, DL; Clarke, SJ; Diakos, C; Engel, A; Eslick, E; Hayes, A; Hsiao, E; Khasraw, M; Pavlakis, N; Roach, PJ; Samra, J; Schembri, GP | 1 |
| Chang, YC; Chen, JS; Chen, SH; Chen, TC; Chou, WC; Hsieh, CH; Hsu, JT; Hwang, TL; Tseng, JH; Yeh, CN; Yeh, TS; Yen, TC | 1 |
| Mansberg, R; Russo, R; Szajer, J; Yung, G | 1 |
| Bucau, M; Couvelard, A; Cros, J; Hentic, O; Laurent-Bellue, A; Lebtahi, R; Mikail, N; Poté, N; Rebours, V; Ruszniewski, P | 1 |
| Capurso, G; Delle Fave, G; Falconi, M; Iannicelli, E; Merola, E; Muffatti, F; Panzuto, F; Partelli, S; Pizzichini, P; Prosperi, D; Rinzivillo, M; Salgarello, M; Schillaci, O; Scopinaro, F | 1 |
| Fu, L; Li, J; Ma, G; Xu, B | 1 |
| Bal, C; Datta Gupta, S; Kumar, R; Parida, GK; Shamim, SA; Singhal, A; Tripathy, S | 1 |
| Castaldi, P; Inzani, F; Lorusso, M; Menghi, R; Rindi, G; Rufini, V; Schinzari, G | 1 |
| Athanasou, NA; Iwata, E; Orosz, Z; Reynolds, J; Tanaka, Y; Teh, J; Whitwell, D | 1 |
| Li, F; Li, J; Luo, Y; Pan, Q; Zhang, S | 1 |
| Acar, E; Kaya, GÇ | 1 |
| Bai, X; Wang, X; Zhang, X | 1 |
| Bromińska, B; Bromiński, G; Czepczyński, R; Dyszkiewicz, W; Gabryel, P; Gut, P; Janicka-Jedyńska, M; Jarmołowska-Jurczyszyn, D; Ruchała, M; Sawicka-Gutaj, N | 1 |
| Cuccurullo, V; Di Stasio, GD; Mansi, L | 1 |
| Ahmadzadehfar, H; Hain, S; Hartmann, L; Hirzebruch, S; Wei, X | 1 |
| Antwi, K; Christ, E; Nicolas, G; Wild, D | 1 |
| Ansquer, C; Bera, G; Bergeret, S; Chanson, P; Charbit, J; Lussey-Lepoutre, C | 1 |
| Chen, D; Hu, S; Li, J; Li, Y; Li, Z; Liu, Z; Long, T; Tang, Y; Yang, N; Zhou, M | 1 |
| Kuang, A; Ma, H; Pan, L; Shen, G; Su, M | 1 |
| Lu, Y | 1 |
| Armani, M; Cadiot, G; Couvelard, A; Cros, J; de Mestier, L; Hentic, O; Lebtahi, R; Rebours, V; Ruszniewski, P; Sauvanet, A | 1 |
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
| Giaccari, A; Petrone, G; Rindi, G; Rufini, V; Salomone, E; Treglia, G | 1 |
| Ciarallo, A; Derbekyan, V; Hickeson, M; Lisbona, R; Makis, W; Novales-Diaz, JA | 1 |
| Freesmeyer, M; Marlowe, RJ; Sänger, P; Schierz, JH | 1 |
| Armbruster, M; Auernhammer, CJ; Haug, A; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Rist, C; Sommer, WH; Sourbron, S; Zech, CJ | 1 |
| Petrun'kin, AM; Tlostanova, MS | 1 |
| Endo, M; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Ohde, Y; Takahashi, T; Yamamoto, N | 1 |
| Endo, M; Kaira, K; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Ohde, Y; Ono, A; Takahashi, T; Yamamoto, N | 1 |
| Bal, C; Gupta, SK; Karunanithi, S; Kumar, R; Lata, S; Malhotra, A; Naswa, N; Patnecha, M; Reddy, RM; Sharma, P | 1 |
| Bal, C; Dhull, VS; Jain, S; Kumar, R; Sharma, P | 1 |
| Armbruster, M; Auernhammer, CJ; Ceelen, F; Haug, A; Reiser, MF; Rist, C; Singnurkar, A; Sommer, WH; Sourbron, S; Zech, CJ | 1 |
| Bergestuen, DS; Khan, MS; Kim, MK; Oberg, K; Rinke, A; Salazar, R; Thirlwell, C; Toumpanakis, C | 1 |
| Bongiovanni, M; Giovanella, L; Treglia, G | 1 |
| Fisker Hag, AM; Haagen Nielsen, C; Johnbeck, CB; Kjaer, A; Knigge, U; Munk Jensen, M | 1 |
| Camp, A; Delpassand, ES; Erion, JL; Espenan, GD; Hamiditabar, M; Krenning, EP; Kvols, LK; Mojtahedi, A; O'Dorisio, TM; Samarghandi, A; Simon, J; Wolfangel, R; Wolin, EM; Zamanian, S | 1 |
| Alimchandani, M; Ellis, R; Kebebew, E; Linehan, WM; Millo, C; Nilubol, N; Patel, D; Quezado, M; Sadowski, SM; Venzon, DJ; Weisbrod, AB | 1 |
| Bando, Y; Harada, M; Ikushima, H; Kubo, M; Matsuzaki, K; Nose, H; Otomi, Y; Otsuka, H; Terazawa, K | 1 |
| Baum, RP; Hommann, M; Hörsch, D; Kaemmerer, D; Kulkarni, HR; Robiller, F | 1 |
| Alifano, M; Cavazza, A; Cesario, A; Filice, A; Lococo, F; Paci, M; Rapicetta, C; Ricchetti, T; Sgarbi, G; Treglia, G; Versari, A | 1 |
| Basu, S; Shrikhande, SV; Sirohi, B | 1 |
| Adler, L; Biersack, HJ; Ezziddin, S; Fischer, HP; Grabellus, F; Höller, T; Nagarajah, J; Pöppel, TD; Sabet, A; Simon, B; Yüce, A | 1 |
| Doran, MG; Fareedy, SB; Gavane, S; Osborne, JR; Spratt, DE; Tarlinton, L; Zelefsky, MJ | 1 |
| Bomanji, J; Panagiotidis, E | 1 |
| Baum, RP; Kulkarni, HR | 2 |
| Alvarado, LA; Ammini, AC; Bal, C; Dwivedi, AK; Kc, SS; Kumar, R; Naswa, N; Sharma, P; Yadav, Y | 1 |
| Santhanam, P; Taïeb, D | 1 |
| Kubota, K; Minamimoto, R; Miyata, Y; Morooka, M; Nakajima, K; Okasaki, M; Sato, T | 1 |
| Abhyankar, A; Basu, S | 1 |
| Akhurst, T; Eu, P; Hicks, RJ; Hofman, MS; Kashyap, R; Kong, G; Michael, M; Zannino, D | 1 |
| Bahri, H; Boucher, E; Clement, B; Cuggia, M; Devillers, A; Edeline, J; Garin, E; Laurence, L; Leghzali, H; Mesbah, H; Raoul, JL | 1 |
| Delle Fave, G; Falconi, M; Maurizi, A; Panzuto, F; Partelli, S; Polenta, V; Rinzivillo, M; Salgarello, M | 1 |
| Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kim, T; Kobayashi, S; Mori, M; Morii, E; Nagano, H; Tatsumi, M; Tomimaru, Y; Wada, H | 1 |
| Adalet, I; Aykan, F; Has Simsek, D; Kuyumcu, S; Sanlı, Y; Turkmen, C; Unal, S | 1 |
| Schillaci, O | 1 |
| Makis, W; McCann, K; McEwan, AJ | 1 |
| Marangmei, C; Sharma, P | 1 |
| Alberini, JL; Cacheux, W; Gauthé, M; Jouve, JL; Lièvre, A; Michel, P; Mitry, E; Richard-Molard, M | 1 |
| Howe, JR | 1 |
| Altinel, D; Cardona, K; Delman, KA; El-Rayes, B; Hawk, N; Kooby, DA; Maithel, SK; Russell, MC; Sarmiento, JM; Schuster, DM; Squires, MH; Staley, CA; Volkan Adsay, N; Winer, JH | 1 |
| Hicks, RJ; Hofman, MS; Kashyap, R; Michael, M | 1 |
| Doi, M; Hara, Y; Hirata, Y; Kasahara, I; Miyamoto, Y; Sekiguchi, Y; Tani, Y | 1 |
| Edeline, J; Garin, E | 1 |
| Lysanyuk, MV; Maistrenko, NA; Romashchenko, PN | 1 |
| Bagci, U; Papadakis, GZ; Patronas, NJ; Sadowski, SM; Stratakis, CA | 1 |
| Kumar, A; Kumar, R; Shamim, SA | 1 |
| Kebebew, E; Summers, RM; Wong, KC; Yao, J | 1 |
| Antonuzzo, L; Bongiovanni, A; Caroli, P; Di Iorio, V; Grana, CM; Ianniello, A; Massri, K; Monti, M; Nicolini, S; Paganelli, G; Sansovini, M; Sarnelli, A; Scarpi, E; Severi, S | 1 |
| Burgess, JR; Kornaczewski, ER; Pointon, OP | 1 |
| Arellano, R; Lopez, E | 1 |
| Bilski, M; Duchnowska, R; Hryciuk, B; Kamiński, G; Szczylik, C; Szymanowski, B; Łapińska, G | 1 |
| Buxbaum, S; Gerardo, L; Henninger, B; Kendler, D; Nilica, B; Rodrigues, M; Stevanovic, V; Uprimny, C; Virgolini, I; Waitz, D; Warwitz, B | 1 |
| Cano-Valderrama, O; Caruso, R; Díaz, E; Durán, HJ; Fabra, I; Garcia, L; Ielpo, B; Malavé, L; Quijano, Y; Vicente, E | 1 |
| Abdulrezzak, U; Kula, M; Kurt, YK; Tutus, A | 1 |
| Berthelsen, AK; Binderup, T; Federspiel, B; Johnbeck, CB; Kjaer, A; Knigge, U; Langer, SW; Loft, A | 1 |
| Basuroy, R; Ramage, JK; Srirajaskanthan, R | 1 |
| Acar, E; Çapa Kaya, G; Durak, H | 1 |
| Bodei, L; Bongiovanni, A; Cingarlini, S; Fantini, L; Ferroni, F; Grana, CM; Ianniello, A; Mezzenga, E; Monti, M; Nicolini, S; Paganelli, G; Sansovini, M; Scarpi, E; Severi, S | 1 |
| Agarwal, KK; Bal, C; Kumar, R; Mukherjee, A | 1 |
| Buck, AK; Higuchi, T; Lapa, C; Samnick, S; Schirbel, A; Weich, A; Werner, RA; Wester, HJ | 1 |
| Bassi, C; Butturini, G; Capelli, P; Cingarlini, S; Citton, E; Davì, MV; De Robertis, R; DʼOnofrio, M; Grego, E; Malfatti, V; Malpaga, A; Ortolani, S; Ruzzenente, A; Salgarello, M; Scarpa, A; Tortora, G; Trentin, C; Vallerio, P | 1 |
| Chan, M; Schembri, GP | 1 |
| Caplin, ME; Karpathakis, A; Lumgair, H; Marelli, L; Pericleous, M; Reiner, J; Thirlwell, C; Toumpanakis, C | 1 |
| Fujihata, S; Kitagami, H; Kondo, Y; Miyai, H; Nonoyama, K; Shimizu, Y; Tanaka, M; Watanabe, K; Yamamoto, M; Yasuda, A | 1 |
| Derlin, T; Hueper, K; Sohns, JM | 1 |
| Liu, Y | 1 |
| Campbell, P; Kok, J; Lin, M; Lin, P; Wong, V | 1 |
| Bergman, J; Kauhanen, S; Korsoff, P; Minn, H; Nuutila, P; Ovaska, J; Salmela, P; Saltevo, J; Sane, T; Seppänen, M; Välimäki, M | 1 |
| Bach-Gansmo, T; Biermann, M; Følling, M; Johnsen, B; Sundin, A; Sørbye, H | 1 |
| Bomanji, JB; Caplin, M; Conry, BG; Dickson, J; Groves, AM; Kayani, I; Win, T | 1 |
| Binderup, T; Federspiel, B; Kjaer, A; Knigge, U; Loft, A | 1 |
| Brambilla, E; Calabrese, F; Lunardi, F; Rea, F; Valente, M; Zucchetta, P; Zuin, A | 1 |
| Binderup, T; Federspiel, B; Hansen, CP; Højgaard, L; Kjaer, A; Knigge, U; Loft, A; Mortensen, J; Pfeifer, A | 1 |
| Choi, SK; Park, CH | 1 |
| Bomanji, J; Caplin, M; Desai, K; Quigley, AM; Toumpanakis, C; Watkins, J; Woodward, N | 1 |
| Alekshun, TJ; Rai, M; Rustagi, T | 1 |
| Billotey, C; Borson-Chazot, F; Bournaud, C; Cornu, C; Giammarile, F; Hervieu, V; Houzard, C; Janier, M; Le Bars, D; Lombard-Bohas, C; Masson, S; Scoazec, JY; Vuillez, JP; Walter, T | 1 |
| Aschoff, P; Pfannenberg, C; Reimold, M; Werner, MK | 1 |
| Karges, W; Mottaghy, FM; Van Binnebeek, S | 1 |
| Alberini, JL; Bellet, D; Champion, L; Edeline, V; Giraudet, AL; Madar, O; Paulmier, B; Pecking, AP; Poinsignon, A | 1 |
| Lindner, A; Manger, B; Manger, K; Schett, G; Wacker, J | 1 |
| Ziessman, HA | 1 |
| Bellan, E; Cambioli, S; Campana, D; Castellucci, P; Fanti, S; Fuccio, C; Grassetto, G; Massaro, A; Montini, GC; Musto, A; Nanni, C; Pantaleo, MA; Rubello, D; Tomassetti, P | 1 |
| Gesuwan, K; Herscovitch, P; Hughes, MS; Kebebew, E; Kitano, M; Libutti, SK; Linehan, WM; Millo, C; Nilubol, N; Phan, GQ; Rahbari, R; Venkatesan, AM; Webb, RC | 1 |
| Farlow, D; Gan, G; Hollands, M; Lam, VW; Laurence, JM; Pleass, HC; Richardson, A; Yao, J | 1 |
| Chowdhury, FU; Gross, MD; Marzola, MC; Rubello, D; Scarsbrook, AF; Waterfield, RT; Wong, KK | 1 |
| Jadvar, H | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Cascini, GL; Catalano, O; Colao, A; Cuccurullo, V; Faggiano, A; Mansi, L; Piunno, A; Scialpi, M | 1 |
| Campitiello, M; Plastino, F; Treglia, G | 1 |
| Bourguet, P | 1 |
| Berner, U; Diehl, M; Döbert, N; Graichen, S; Grünwald, F; Hamscho, N; Menzel, C; Risse, JH | 1 |
| Delbeke, D; Martin, WH; Scanga, DR | 1 |
| Diehl, M; Döbert, N; Grünwald, F; Hamscho, N; Menzel, C; Zaplatnikov, K | 1 |
| Nguyen, BD | 1 |
| Barrington, SF; Carroll, PV; Kumar, J; Powrie, JK; Spring, M | 1 |
| Dimitrakopoulou-Strauss, A; Eisenhut, M; Georgoulias, V; Haberkorn, U; Koukouraki, S; Strauss, LG | 1 |
| Belhocine, T; Bolle, S; Dargent, JL; Flamen, P; Frühling, J; Hustinx, R; Letesson, G; Pierard, GE; Rigo, P | 1 |
| Fanti, S; Nanni, C; Rubello, D | 1 |
| Mottaghy, FM; Reske, SN | 1 |
| Boerner, AR; Galanski, M; Knapp, WH; von Falck, C | 1 |
| Drobik, P; Junik, R; Kobus-Błachnio, K; Małkowski, B | 1 |
| Choi, JY; Chong, S; Chung, MJ; Kim, BT; Lee, JY; Lee, KS; Oh, DK; Yi, CA | 1 |
| Chong, S; Lee, KS | 1 |
| Chung, JH; Kim, SE; Kim, YK; Lee, WW; Park, SY; Song, YS | 1 |
| Baboï, L; Beuf, O; Langlois, JB; Lartizien, C; Milot, L; Pilleul, F; Roche, C; Scoazec, JY | 1 |
| Bomanji, JB; Caplin, M; Conway, G; Dickson, J; Ell, PJ; Gacinovic, S; Groves, A; Kayani, I; Win, T | 1 |
| Al-Nahhas, A; Khan, S; Lloyd, C; Rubello, D; Szyszko, T; Win, Z | 1 |
| Hawkins, RA | 1 |
| Adams, S; Baum, R; Hör, G; Rink, T; Schumm-Dräger, PM; Usadel, KH | 1 |
| Chierichetti, F; Ferlin, G; Gasparoni, P; Liessi, G; Pasquali, C; Pedrazzoli, S; Rubello, D; Sperti, C | 1 |
| Bihl, H; Lang, O | 1 |
| Bomanji, JB; Costa, DC; Ell, PJ; Le Rest, C; Townsend, CE; Visvikis, D | 1 |
| Angelberger, P; Dudczak, R; Füger, B; Kletter, K; Kurtaran, A; Leimer, M; Li, SR; Novotny, C; Patri, P; Raderer, M; Traub, T; Virgolini, I; Wogritsch, S | 1 |
| Bombardieri, E; Chiti, A; De Deckere, E; Maccauro, M; Savelli, G | 1 |
41 review(s) available for fluorodeoxyglucose f18 and Neuroendocrine Tumors
| Article | Year |
|---|---|
Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neuroendocrine Tumors; Prognosis; Receptors, Somatostatin | 2022 |
Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.
Topics: Adrenocorticotropic Hormone; Biological Products; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Somatostatin; Tyrosine | 2022 |
Gastro-Entero-Pancreatic Tumors: FDG Positron Emission Tomography/Computed Tomography.
Topics: Copper Radioisotopes; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin | 2023 |
Advances in Functional Imaging in the Assessment of Head and Neck Cancer.
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radioactive Tracers; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2019 |
[Pulmonary carcinoids and carcinoids of the small intestine].
Topics: Carcinoid Tumor; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Intestine, Small; Lung Neoplasms; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2019 |
The Role of PET/CT in the Imaging of Pancreatic Neoplasms.
Topics: Adenocarcinoma; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Topics: Acetates; Carbon Radioisotopes; Dideoxynucleosides; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Lung Neoplasms; Methionine; Misonidazole; Neoplasm Staging; Neuroendocrine Tumors; Peptides; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Quinolines; Radiopharmaceuticals; Sensitivity and Specificity | 2020 |
Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres.
Topics: Brachytherapy; Fluorodeoxyglucose F18; Humans; Liver; Liver Neoplasms; Microspheres; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Yttrium Radioisotopes | 2020 |
Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Intestinal Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Stomach Neoplasms | 2020 |
Variants and Pitfalls of PET/CT in Neuroendocrine Tumors.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysis.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2021 |
Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Somatostatin | 2017 |
Neuroendocrine Tumor Arising in a Tailgut Cyst: A Rare Presacral Tumor.
Topics: Adult; Biopsy; Cysts; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Hamartoma; Humans; Magnetic Resonance Imaging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Sacrococcygeal Region; Soft Tissue Neoplasms | 2019 |
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Topics: Animals; Dihydroxyphenylalanine; Dimerization; Edetic Acid; Fluorodeoxyglucose F18; Glucagon-Like Peptide-1 Receptor; Humans; Indium Radioisotopes; Insulinoma; Ligands; Mice; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin | 2019 |
Molecular imaging for neuroendocrine tumours.
Topics: Carcinoma, Neuroendocrine; Fluorodeoxyglucose F18; Glucagon-Like Peptide-1 Receptor; Humans; Molecular Imaging; Neoplasm Staging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Tomography, X-Ray Computed | 2019 |
Novel PET tracers: added value for endocrine disorders.
Topics: Dihydroxyphenylalanine; Endocrine System Diseases; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Digestive System Neoplasms; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Magnetic Resonance Imaging; Molecular Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radionuclide Imaging; Receptors, Somatostatin; Sensitivity and Specificity; Stomach Neoplasms; Surveys and Questionnaires; Tomography, X-Ray Computed; Ultrasonography | 2014 |
[The relevance of PET/CT for the surgical management of neuroendocrine neoplasms].
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Humans; Molecular Imaging; Multimodal Imaging; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Positron-Emission Tomography; Receptors, Somatostatin; Sensitivity and Specificity; Somatostatin; Tomography, X-Ray Computed | 2014 |
PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.
Topics: Bronchial Neoplasms; Carcinoid Tumor; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Enterochromaffin Cells; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Thyroid Neoplasms | 2014 |
Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Patient Selection; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, X-Ray Computed | 2014 |
Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, X-Ray Computed | 2014 |
Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Topics: Adrenal Gland Neoplasms; Carbidopa; Carcinoid Tumor; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Dopamine Agents; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed | 2014 |
Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
Topics: Digestive System Neoplasms; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Patient Care Planning; Positron-Emission Tomography; Practice Guidelines as Topic; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Thyroid Neoplasms; Tomography, X-Ray Computed | 2015 |
Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chromogranin A; Digestive System Surgical Procedures; Embolization, Therapeutic; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms; Magnetic Resonance Imaging; Malignant Carcinoid Syndrome; Metastasectomy; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Serotonin; Tomography, X-Ray Computed | 2016 |
Well-differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients.
Topics: Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; Chromogranin A; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Neuroendocrine Tumors; Outcome Assessment, Health Care; Positron-Emission Tomography; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2018 |
[Positron emission tomography in neuroendocrine tumours].
Topics: APUD Cells; Drug and Narcotic Control; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Norway; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity | 2009 |
Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer.
Topics: Adult; Aged; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasms; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2011 |
[Hypertrophic osteoarthropathy. Bamberger-Marie disease].
Topics: Adult; Cardia; Cooperative Behavior; Diagnosis, Differential; Early Diagnosis; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastroscopy; Humans; Interdisciplinary Communication; Male; Multimodal Imaging; Neoplasm Invasiveness; Neuroendocrine Tumors; Osteoarthropathy, Secondary Hypertrophic; Paraneoplastic Syndromes; Positron-Emission Tomography; Prognosis; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed | 2011 |
Contemporary nuclear medicine imaging of neuroendocrine tumours.
Topics: Chromaffin System; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2012 |
Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
Topics: Animals; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Stomach Neoplasms | 2012 |
Nuclear medicine in NET.
Topics: Biomarkers, Tumor; Cell Proliferation; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Multimodal Imaging; Neoplasm Staging; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Receptors, Peptide; Receptors, Somatostatin; Tomography, X-Ray Computed | 2012 |
Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors?
Topics: Diagnostic Imaging; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multidetector Computed Tomography; Multimodal Imaging; Neoplasm Proteins; Neuroendocrine Tumors; Nuclear Medicine Department, Hospital; Oligopeptides; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Somatostatin; Tomography, X-Ray Computed; Ultrasonography | 2012 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in digestive system neoplasms].
Topics: Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed | 2003 |
[Positron-emission tomography in oncology].
Topics: Colorectal Neoplasms; Evidence-Based Medicine; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Functional imaging of neuroendocrine tumours with PET.
Topics: Animals; Biogenic Amines; Enzyme Inhibitors; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Somatostatin; Tomography, X-Ray Computed | 2006 |
Spectrum of findings and usefulness of integrated PET/CT in patients with known or suspected neuroendocrine tumors of the lung.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2007 |
PET imaging in endocrine tumours.
Topics: Adrenal Gland Neoplasms; Endocrine Gland Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Parathyroid Neoplasms; Pituitary Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms | 2008 |
Nuclear medicine imaging of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; 5-Hydroxytryptophan; Antibodies, Monoclonal; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Levodopa; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Tomography, Emission-Computed | 2001 |
12 trial(s) available for fluorodeoxyglucose f18 and Neuroendocrine Tumors
| Article | Year |
|---|---|
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Topics: Adult; Aged; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate | 2020 |
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Topics: Capecitabine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies | 2021 |
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Topics: Adult; Aged; Digestive System Neoplasms; Disease Progression; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Predictive Value of Tests; Quality of Life; Radiopharmaceuticals; Receptors, Somatostatin; Texas; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2015 |
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Topics: Adult; Aged; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Receptors, Peptide; Safety; Thyroid Nuclear Factor 1; Transcription Factors | 2016 |
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography | 2016 |
The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Carcinoma, Medullary; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thyroid Neoplasms | 2009 |
18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Predictive Value of Tests; Prognosis | 2010 |
18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Topics: Adult; Aged; Cell Differentiation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2011 |
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Topics: Adolescent; Adult; Aged; Dopamine; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; von Hippel-Lindau Disease; Young Adult | 2011 |
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prognosis; Radionuclide Imaging; Radiopharmaceuticals | 2006 |
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gastrointestinal Agents; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Stomach Neoplasms; Technetium Tc 99m Dimercaptosuccinic Acid; Thyroid Neoplasms; Tomography, Emission-Computed | 1998 |
140 other study(ies) available for fluorodeoxyglucose f18 and Neuroendocrine Tumors
| Article | Year |
|---|---|
Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
Topics: Adult; Aged; China; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Rectal Neoplasms; Sensitivity and Specificity | 2021 |
The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Retrospective Studies | 2022 |
Letter to Editor Re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms" (https://doi.org/10.1016/j.acra.2021.10.004).
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radionuclide Imaging | 2022 |
Response to Letter to Editor re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms".
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radionuclide Imaging | 2022 |
18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Findings in a Patient With Primary Renal Well-Differentiated Neuroendocrine Tumor.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radionuclide Imaging | 2022 |
Radioiodine Uptake in Incidentally Detected Neuroendocrine Tumor: Correlative Imaging With FDG PET/CT and 68 Ga-DOTATATE PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed | 2022 |
Cardiac hemangioma mimicking a neuroendocrine tumor on
Topics: Fluorodeoxyglucose F18; Heart Neoplasms; Hemangioma; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals | 2022 |
Somatostatin Receptor-negative and Fluorodeoxyglucose-positron Emission Tomography-positive Lung Neuroendocrine Tumor G1 Exhibiting Cyclic Cushing's Syndrome.
Topics: ACTH Syndrome, Ectopic; Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cushing Syndrome; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Positron-Emission Tomography; Receptors, Somatostatin; Somatostatin | 2022 |
Metastasis From Clear Cell Renal Cell Carcinoma Mimicking Well-Differentiated Pancreatic Neuroendocrine Tumor at 18F-FDG and 68Ga-DOTATOC PET/CT.
Topics: Aged, 80 and over; Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Neuroectodermal Tumors, Primitive; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2022 |
Gastroenteropancreatic neuroendocrine neoplasm imaging: standard reporting templates.
Topics: Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Receptors, Somatostatin | 2022 |
Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors.
Topics: Bone Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Factors | 2022 |
Impact of FDG PET/CT Scan in Changing Management of Well-Differentiated Neuroendocrine Tumors With Ki67 Index Less Than or Equal to 5.
Topics: Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Somatostatin; Tomography, X-Ray Computed | 2022 |
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cell Proliferation; Fluorodeoxyglucose F18; Glycolysis; Humans; Ki-67 Antigen; Lung; Lung Neoplasms; Middle Aged; Molecular Imaging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Receptors, Somatostatin; Retrospective Studies; Tumor Burden | 2023 |
Metastatic primary breast neuroendocrine neoplasms: a case series.
Topics: Adult; Breast Neoplasms; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasms, Second Primary; Neuroendocrine Tumors; Prognosis; Retrospective Studies | 2023 |
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Digestive System Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
Dual [
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Detection of Bone Metastases by
Topics: Bone Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Ki-67 Antigen; Neuroendocrine Tumors; Osteolysis; Positron Emission Tomography Computed Tomography; Receptors, Somatostatin; Retrospective Studies | 2022 |
Diagnostic performance and impact on patient management of [68Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut.
Topics: Colorectal Neoplasms; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
A neuroendocrine tumor within an anterior mediastinal mature teratoma: a case report.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Mediastinal Neoplasms; Mediastinum; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Teratoma | 2022 |
[Traumatic Neuroma Mimicking Lymph Node Metastasis of Pancreatic Neuroendocrine Neoplasms Developed after Pancreatoduodenectomy-A Case Report].
Topics: Aged; Bile Ducts; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Neuroendocrine Tumors; Neuroma; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2022 |
Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2023 |
Washout-Computed Tomography Discriminates Pulmonary "Fat-poor" Hamartomas From Neuroendocrine Neoplasms: A Simple Method in the Radiomics Era.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2023 |
Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2023 |
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors.
Topics: Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity | 2023 |
68 Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis | 2020 |
Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.
Topics: Corticotropin-Releasing Hormone; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2020 |
18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
Topics: Diagnosis, Differential; Diffusion; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
PET/CT in Evaluation of Low Backache Due to Sacral Nerve Root Involvement: Inflammatory and Malignant Involvement.
Topics: Adult; Colitis, Ulcerative; Female; Fluorodeoxyglucose F18; Humans; Low Back Pain; Male; Middle Aged; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Spinal Nerve Roots | 2020 |
Combined 68Ga-DOTATOC and 18F-FDG PET Predicts a Double Component With Different Grade of a Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 1.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis | 2020 |
Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography | 2020 |
Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Preoperative Period; Radioactive Tracers; Retrospective Studies; Risk Assessment; Young Adult | 2020 |
Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Quality of Life; Receptors, Somatostatin; Retrospective Studies; Treatment Outcome | 2021 |
Clinical usefulness of FDG-PET for management of well-differentiated digestive neuroendocrine tumors.
Topics: Fluorodeoxyglucose F18; France; Humans; Neoplasm Metastasis; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Surveys and Questionnaires | 2020 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Temozolomide | 2021 |
Topics: Adult; Aged; Cohort Studies; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Receptors, Somatostatin; World Health Organization; Young Adult | 2021 |
Collision of Solid Pseudopapillary Tumor and Neuroendocrine Tumor of the Pancreas on 18F-FDG PET/CT.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
The superiority of [
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Liver Neoplasms; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Quinolines | 2021 |
Detection of Cauda Equine Syndrome With 18F-FDG PET/CT and Leptomeningeal Metastasis by 68Ga-DOTATATE in the Same Patient With Large Cell Neuroendocrine Carcinoma of Lung.
Topics: Cauda Equina Syndrome; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography | 2021 |
Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.
Topics: Adult; Aged; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Outcome Assessment, Health Care; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Peptide | 2021 |
Appendiceal Neuroendocrine Tumor Detected by 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Ultrasonography | 2017 |
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Prospective Studies; Receptors, Somatostatin | 2017 |
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Grading; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Receptors, Somatostatin; Retrospective Studies | 2017 |
68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Taiwan; Young Adult | 2018 |
Adrenocorticotropic Hormone-Secreting Neuroendocrine Tumor of the Rectum Demonstrated on 68Ga-DOTATATE and 18F-FDG PET Imaging.
Topics: Adrenocorticotropic Hormone; Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Rectal Neoplasms | 2017 |
18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Von Hippel-Lindau Tumor Suppressor Protein | 2018 |
Clinical Usefulness of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Rate | 2018 |
18F-FDG PET/CT in Primary Hepatic Neuroendocrine Tumors.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography | 2018 |
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Topics: Adenocarcinoma; Aged; Edetic Acid; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neuroendocrine Tumors; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms | 2018 |
Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Topics: Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Intestinal Neoplasms; Ki-67 Antigen; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Radiopharmaceuticals; Stomach Neoplasms | 2018 |
Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
Topics: Adult; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Lymph Nodes; Male; Neuroendocrine Tumors; Nose Neoplasms; Organometallic Compounds; Pancreatic Neoplasms; Plasmacytoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2018 |
18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Topics: Aged; Edetic Acid; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm Metastasis; Neuroendocrine Tumors; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals | 2019 |
Primary Hepatic Neuroendocrine Tumor: Pretherapy and Posttherapy FDG PET/CT Finding.
Topics: Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
18F-FDG PET/CT and nestin expression as prognostic tools in pulmonary neuroendocrine tumours.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nestin; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2019 |
Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor.
Topics: Aged; Chemoradiotherapy; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Healthy Volunteers; Heterocyclic Compounds, 1-Ring; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiometry; Radiopharmaceuticals; Tissue Distribution | 2019 |
Primary Spinal Poorly Differentiated Neuroendocrine Tumor Displayed on FDG PET/CT.
Topics: Biological Transport; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Spine | 2019 |
Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT.
Topics: Aged; Biopsy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multiple Myeloma; Neoplasm Grading; Neoplasms, Multiple Primary; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography | 2019 |
Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.
Topics: Biomarkers, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2019 |
A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT.
Topics: ACTH Syndrome, Ectopic; Adult; Cell Differentiation; Female; Fluorodeoxyglucose F18; Glucose; Humans; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Gastric neuroendocrine carcinoma staged and followed with (18)F-FDG PET/CT--a report of 3 cases.
Topics: Aged; Endoscopy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Helicobacter pylori; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neuroendocrine Tumors; Radiography; Radionuclide Imaging; Stomach Neoplasms | 2013 |
Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2014 |
Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Topics: Contrast Media; Coordination Complexes; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
[Sensitivity of PET with 18F-fluorodesoxyglucose in the diagnosis of neuroendocrine tumors of the lungs].
Topics: Adult; Aged; Carcinoid Tumor; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Small Cell Lung Carcinoma | 2013 |
Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors.
Topics: Aged; Antigens, CD34; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microvessels; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Microvessels; Middle Aged; Neovascularization, Pathologic; Neuroendocrine Tumors; Orotate Phosphoribosyltransferase; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymidylate Synthase; Thymus Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Retrospective Studies; Stomach Neoplasms; Tomography, X-Ray Computed | 2014 |
Lymphoma as a second malignancy in a patient with neuroendocrine tumor: mimicking dedifferentiation on dual-tracer PET/CT with 68Ga-DOTANOC and 18F-FDG.
Topics: Cell Dedifferentiation; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Multimodal Imaging; Neoplasms, Second Primary; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Rare sinonasal small cell neuroendocrine carcinoma evaluated by F-18-FDG PET/MRI.
Topics: Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neuroendocrine Tumors; Nose Neoplasms; Radionuclide Imaging | 2014 |
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Monitoring; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Multimodal Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Tomography, X-Ray Computed; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2014 |
Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; von Hippel-Lindau Disease; Young Adult | 2014 |
Comparing the performance of visual estimation and standard uptake value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography for detecting malignancy in pancreatic tumors other than invasive ductal carcinoma.
Topics: Adenoma; Adult; Aged; Cystadenoma, Serous; Diagnosis, Differential; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.
Topics: Adult; Cell Proliferation; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organotechnetium Compounds; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Somatostatin; Tomography, X-Ray Computed | 2014 |
Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Topics: Adult; Aged; Aged, 80 and over; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis | 2014 |
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prevalence; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms | 2014 |
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
Topics: Adult; Aged; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Muscles; Neoplasm Grading; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, X-Ray Computed; Tumor Burden | 2014 |
The use of 99mTc-HYNIC-TOC and 18F-FDG PET/CT in the evaluation of duodenal neuroendocrine tumor with atypical and extensive metastasis responding dramatically to a single fraction of PRRT with 177Lu-DOTATATE.
Topics: Adult; Duodenal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Organotechnetium Compounds; Positron-Emission Tomography; Receptors, Peptide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Topics: Aged; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Probability; Prognosis; Proportional Hazards Models; Radionuclide Imaging; ROC Curve; Stomach Neoplasms; Treatment Outcome | 2014 |
The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
Topics: Aged; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Diagnosis, Differential; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; World Health Organization | 2015 |
Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Intestinal Neoplasms; Ki-67 Antigen; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed | 2014 |
Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
Topics: Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2014 |
Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the Cecum.
Topics: 3-Iodobenzylguanidine; Carcinoma, Acinar Cell; Cecal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Parotid Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Multiple Pathologies Seen on a Single Contrast-Enhanced 18F-FDG PET/CT: Reiteration of Lessons Previously Learned.
Topics: Breast Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphadenitis; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
The Supporting Role of (18)FDG-PET in Patients with Neuroendocrine Tumors.
Topics: Female; Fluorodeoxyglucose F18; Humans; Indium Radioisotopes; Male; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Somatostatin | 2015 |
Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Somatostatin; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2015 |
Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
Topics: Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2015 |
Ectopic ACTH syndrome caused by desmopressin-responsive thymic neuroendocrine tumor.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Deamino Arginine Vasopressin; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Gene Expression; Humans; Hydrocortisone; Neuroendocrine Tumors; Pituitary ACTH Hypersecretion; Positron-Emission Tomography; Receptors, Vasopressin; Thymus Neoplasms; Tomography, X-Ray Computed | 2015 |
Reply: Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
Topics: Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2015 |
[Modern technologies and diagnostics in treatment of neuroendocrine tumors of the pancreas].
Topics: Adult; Angiography; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2015 |
Ectopic ACTH and CRH Co-secreting Tumor Localized by 68Ga-DOTA-TATE PET/CT.
Topics: Adrenocorticotropic Hormone; Corticotropin-Releasing Hormone; Cushing Syndrome; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Thymus Neoplasms; Tomography, X-Ray Computed; Young Adult | 2015 |
Pancreatic Tumor Growth Prediction with Multiplicative Growth and Image-Derived Motion.
Topics: Algorithms; Artificial Intelligence; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Motion; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Positron-Emission Tomography; Retrospective Studies; Succinate Dehydrogenase; Young Adult | 2016 |
Neuroendocrine Malignancy Diagnosed via CT-Guided Percutaneous Biopsy of an Isolated Abnormal Cardiophrenic Lymph Node: Case Report.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Lymph Nodes; Male; Middle Aged; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review.
Topics: Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2016 |
Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Topics: Adult; Aged; Biological Transport; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Receptors, Somatostatin; Retrospective Studies | 2016 |
Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study.
Topics: Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; World Health Organization | 2016 |
Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Topics: Adult; Aged; Drug Combinations; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2016 |
Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2017 |
FDG DOTANOC Mismatch in In Vivo Characterization and Grading of Neuroendocrine Tumor.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed imaging.
Topics: Aged; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2017 |
Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Topics: Adult; Aged; Aged, 80 and over; Decision Making; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreas; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Preoperative Period; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2017 |
Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Primary mesenteric neuroendocrine tumor that changed its internal composition from cystic to solid: a case report.
Topics: Aged; Disease Progression; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Mesentery; Neuroendocrine Tumors; Peritoneal Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2017 |
68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG.
Topics: Chordoma; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
[18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed; von Hippel-Lindau Disease | 2009 |
A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Receptors, Somatostatin; Retrospective Studies; Tomography, X-Ray Computed | 2009 |
Pulmonary inflammatory myofibroblastic tumour with unusual octreoscan uptake: two reports.
Topics: Adult; Female; Fibroblasts; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Neoplasms, Muscle Tissue; Neuroendocrine Tumors; Pentetic Acid; Somatostatin; Tomography, X-Ray Computed | 2010 |
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed | 2010 |
[A case of pancreatic neuroendocrine tumor with multiple hepatic metastasis].
Topics: Aged; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin.
Topics: Biopsy; Colorectal Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography | 2011 |
Gastric adenocarcinoma? Looks similar but behaves differently!
Topics: Adenocarcinoma; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.
Topics: Adenocarcinoma; Aged; Biopsy; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Fluorodeoxyglucose F18; Humans; Male; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Spinal Neoplasms; Spine; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2011 |
Functional imaging of neuroendocrine tumors.
Topics: 5-Hydroxytryptophan; Animals; Contrast Media; Dihydroxyphenylalanine; Dopamine; Ephedrine; Etomidate; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Peptides; Positron-Emission Tomography; Radioactive Tracers; Radiopharmaceuticals; Somatostatin | 2011 |
General nuclear medicine.
Topics: Bone and Bones; Fluorodeoxyglucose F18; Humans; Infections; Multimodal Imaging; Neuroendocrine Tumors; Nuclear Medicine; Positron-Emission Tomography; Thyroid Neoplasms; Tomography, X-Ray Computed | 2011 |
When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors?
Topics: Aged; Fluorodeoxyglucose F18; Humans; Liver; Male; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Cystadenoma, Serous; Decision Support Techniques; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Staging and treatment response evaluation in a metastatic neuroendocrine tumor of the pancreas with G2 grading: insights from multimodality diagnostic approach by F-18-FDG and Ga-68-DOTANOC PET/CT.
Topics: Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Radionuclide Imaging; Somatostatin; Treatment Outcome | 2013 |
Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Topics: 3-Iodobenzylguanidine; Biological Transport; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Radiopharmaceuticals; Reproducibility of Results; Tissue Distribution; Tomography, Emission-Computed | 2003 |
Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
Topics: Fluorodeoxyglucose F18; Neoplasm Recurrence, Local; Nervous System Neoplasms; Neural Crest; Neuroendocrine Tumors; Patient Care Management; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed | 2004 |
Pancreatic neuroendocrine tumor with portal vein tumor thrombus: PET demonstration.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Portal Vein; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Venous Thrombosis | 2005 |
18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Cushing Syndrome; Female; Fluorodeoxyglucose F18; Humans; Male; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma.
Topics: Aged; Carcinoma, Merkel Cell; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Skin Neoplasms | 2006 |
18F-DOPA PET/CT and neuroendocrine tumours.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2006 |
Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation.
Topics: Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Image Processing, Computer-Assisted; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2007 |
The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
Topics: Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity | 2006 |
Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung.
Topics: Aged; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Lung Neoplasms; Male; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Multimodal imaging for the detection and characterization of liver lesions in a mouse model of neuroendocrine tumor.
Topics: Animals; Autoradiography; Biopsy; Cell Line, Tumor; Chromogranin A; Diagnostic Imaging; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Injections; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Neuroendocrine Tumors; Radiopharmaceuticals; Time Factors | 2008 |
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Gallium; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2008 |
Pancreatic tumors: imaging with PET.
Topics: Adenocarcinoma; Carbon Radioisotopes; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Levodopa; Neuroendocrine Tumors; Pancreatic Neoplasms; Sensitivity and Specificity; Serotonin; Tomography, Emission-Computed | 1995 |
Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
[Somatostatin receptor scintigraphy (SRS) in a neuroendocrine pancreatic tumor: why SPECT?].
Topics: Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ultrasonography | 2000 |
Functional imaging of malignant paragangliomas and carcinoid tumours.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Carcinoid Tumor; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
Topics: Adenocarcinoma; Adult; Carcinoid Tumor; Fluorodeoxyglucose F18; Heterocyclic Compounds; Humans; Intestinal Neoplasms; Ligands; Lung Neoplasms; Lymphoma; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Tyrosine | 2001 |